Cns Provides Update on Development Agreement for Wp1122

CNS Provides Update on Development Agreement for WP1122

CNS Pharmaceuticals, a biotech company focused on the development of cancer treatments, has recently provided an update on its development agreement for WP1122. WP1122 is a prodrug of 2-deoxy-D-glucose (2DG) that has been shown to inhibit glycolysis, a process essential for cancer cells to produce energy.

In November 2019, CNS entered into a development agreement with WPD Pharmaceuticals, a Polish biotech company, to advance the clinical development of WP1122. As per the agreement, WPD will conduct preclinical and clinical studies in Europe and Asia, while CNS will focus on clinical development in the United States.

CNS has now reported that WPD has successfully completed the preclinical studies for WP1122, including pharmacology, toxicology, and formulation optimization. The studies demonstrated that WP1122 has good pharmacokinetic properties and excellent safety profiles in animal models.

Furthermore, WPD has initiated the clinical development of WP1122 in Poland, with the enrollment of the first patient in a Phase 1b/2 study. The study is expected to enroll up to 30 patients with recurrent glioblastoma, a deadly form of brain cancer, who have failed standard therapy. The primary objective of the study is to determine the safety and tolerability of WP1122 in combination with radiation therapy and temozolomide, a chemotherapy drug commonly used to treat glioblastoma.

CNS is excited about these developments and looks forward to the results of the clinical trial, which will provide valuable information on the safety and efficacy of WP1122 in humans. The company believes that WP1122 has the potential to become a significant new therapy for the treatment of glioblastoma and other forms of cancer.

In conclusion, the update provided by CNS on the development agreement for WP1122 is highly encouraging for the future of cancer treatment. The success of the preclinical studies and the initiation of the clinical trial in Poland represent important milestones in the development of this drug. We eagerly await the results of the trial and hope that WP1122 will prove to be a game-changer in the fight against cancer.